Impact of Perampanel for First-Episode Seizures versus Usual Care on Clinical Outcome and Safety Profile Aspects of the Thai Experience.
| Title: | Impact of Perampanel for First-Episode Seizures versus Usual Care on Clinical Outcome and Safety Profile Aspects of the Thai Experience. |
|---|---|
| Authors: | Boontoterm P; Neurological Surgery Unit, Department of Surgery, Phramongkutklao Hospital, Bangkok, Thailand.; Sakoolnamarka S; Neurological Surgery Unit, Department of Surgery, Phramongkutklao Hospital, Bangkok, Thailand.; Urasyanandana K; Neurological Surgery Unit, Department of Surgery, Phramongkutklao Hospital, Bangkok, Thailand.; Fuengfoo P; Neurological Surgery Unit, Department of Surgery, Phramongkutklao Hospital, Bangkok, Thailand. |
| Source: | Journal of epilepsy research [J Epilepsy Res] 2024 Dec 10; Vol. 14 (2), pp. 81-93. Date of Electronic Publication: 2024 Dec 10 (Print Publication: 2024). |
| Publication Type: | Journal Article |
| Language: | English |
| Journal Info: | Publisher: Korean Epilepsy Society Country of Publication: Korea (South) NLM ID: 101577886 Publication Model: eCollection Cited Medium: Print ISSN: 2233-6249 (Print) Linking ISSN: 22336249 NLM ISO Abbreviation: J Epilepsy Res Subsets: PubMed not MEDLINE |
| Imprint Name(s): | Original Publication: Seoul : Korean Epilepsy Society |
| Abstract: | Background and Purpose: Epilepsy increases poor outcomes in patients with post-traumatic brain injury and brain tumor-related epilepsy, for whom early seizure control is essential. Perampanel (PER) was a known third-generation antiepileptic drug for treatment all types of seizures. The objective of the study is to compare clinical outcomes and safety of PER administration as monotherapy.; Methods: A prospective study of all 84 patients assigned to PER monotherapy (PER group, n=36) and other first-line antiepileptic drugs (n=48). Clinical outcomes parameters were measured by the prevalence of patients with a diminish in seizure frequency at 50% in 28 days. From November 1, 2020 to April 30, 2024, comparing the PER group with usual care. Clinical outcomes included adherence rate and seizure-free proportion at 28 days and 6 months. Adverse drug reactions were recorded in both groups.; Results: There was no difference in demographic data and incidence of adverse drug reactions between two groups. Median PER dosage was 4 mg (range, 2-12 mg). Compared to other antiepileptic drugs, the PER group had a prevalence of 50% responder rate at 28 days and 6 months significantly were 75%, 81%, 65%, and 51% respectively. Common adverse drug reactions were somnolence and dizziness.; Conclusions: PER administration as monotherapy demonstrated good efficacy and less adverse drug reactions. Low dosages helped to decrease adverse drug reactions and improved retention rate.; (Copyright © 2024 Korean Epilepsy Society.) |
| Competing Interests: | Conflict of Interests: There is no conflict of interest between the authors. |
| References: | Seizure. 2006 Oct;15(7):504-8. (PMID: 16861012); Neurology. 2012 Aug 7;79(6):589-96. (PMID: 22843280); Epilepsy Behav Case Rep. 2017 Dec 01;9:1-5. (PMID: 29707476); Epilepsia. 2013 Jan;54(1):117-25. (PMID: 22905857); Neurology. 2015 Sep 15;85(11):950-7. (PMID: 26296511); Epilepsia Open. 2020 Jun 07;5(2):274-284. (PMID: 32524053); Epilepsy Res. 1999 Oct;37(1):81-7. (PMID: 10515178); Epilepsia. 2014 Jan;55 Suppl 1:13-5. (PMID: 24400692); Epilepsia. 2001 Oct;42(10):1255-60. (PMID: 11737159); Brain Res. 1994 Feb 28;638(1-2):36-44. (PMID: 8199874); Neurology. 2012 May 1;78(18):1408-15. (PMID: 22517103); Epilepsia Open. 2022 Mar;7(1):67-74. (PMID: 34741590); Acta Neurol Scand Suppl. 2013;(197):36-43. (PMID: 23480155); Seizure. 2021 Mar;86:109-115. (PMID: 33592505); Curr Neuropharmacol. 2009 Jun;7(2):77-82. (PMID: 19949565); Epilepsia. 2013 Aug;54(8):1481-9. (PMID: 23663001); Epilepsy Behav. 2020 Jan;102:106655. (PMID: 31812902); Epilepsia. 2020 Jun;61(6):1109-1119. (PMID: 32511754); Epilepsy Res. 2015 Feb;110:146-56. (PMID: 25616467); JAMA Neurol. 2018 Mar 1;75(3):279-286. (PMID: 29279892); Epilepsia. 1981 Feb;22(1):1-10. (PMID: 6781884); Epilepsia. 2011 Jul;52(7):1331-40. (PMID: 21635236); Seizure. 2018 Jan;54:61-66. (PMID: 29288911) |
| Contributed Indexing: | Keywords: Adverse drug reaction; Antiepileptic drugs; Epilepsy; Seizures; Traumatic brain injury |
| Entry Date(s): | Date Created: 20241225 Latest Revision: 20250104 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC11664051 |
| DOI: | 10.14581/jer.24014 |
| PMID: | 39720193 |
| Database: | MEDLINE |
Journal Article